Keybanc analyst Paul Knight maintains Harvard Bioscience (NASDAQ:HBIO) with a Overweight and lowers the price target from $7 to $5.
- Headlines
- Keybanc Maintains Overweight on Harvard Bioscience, Lowers Price Target to $5
Keybanc Maintains Overweight on Harvard Bioscience, Lowers Price Target to $5
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Price
Unlock the Full List
Latest
02:52
UFC is seeking to obtain more than 1 billion dollars in revenue from the next round of Television broadcasting rights Trade.
02:46
In 5 years, the scale has grown over tenfold, and cross-border E-Commerce has become a new engine for foreign trade development.
02:40
Intercontinental Exchange: As of the week ending January 7, speculators' net long positions in Brent Crude Oil increased by 39,944 contracts to 226,859 contracts. Speculators' net long positions in RBOB Gasoline increased by 9,504 contracts to 32,377 contracts.
ICE-1.71%